Anticoagulant Therapy in Moderate to Severe COVID-19 Patients
Coronavirus disease-19 (COVID-19) has a spectrum of severity from no symptoms to serious complications. Coagulopathy is a serious complication of COVID-19, and that condition is a marker of poor prognosis. Anticoagulant drugs are often used as prophylaxis and thrombosis therapy to treat COVID-19 pat...
Main Authors: | Agus Fitriyanto Achmad, Yuni Iswati Raharjani, Zidni Setyaningrum, Bagus Andi Pramono, Dita Ria Selvyana, Sri Pramesthi Wisnu Bowo Negoro |
---|---|
Format: | Article |
Language: | English |
Published: |
Universitas Muhammadiyah Yogyakarta
2022-01-01
|
Series: | Mutiara Medika |
Subjects: | |
Online Access: | https://journal.umy.ac.id/index.php/mm/article/view/11634 |
Similar Items
-
Therapeutic inefficacy of protocol driven intravenous unfractionated heparin infusion in the current era
by: Kayla Torppey, et al.
Published: (2023-10-01) -
Ewolucja leczenia przeciwzakrzepowego – od kleszcza i pijawki do tabletki
by: Wiesława Bednarek, et al.
Published: (2010-08-01) -
INTRAOPERATIVE ANTICOAGULATION MONITORIZATION IN VASCULAR SURGERY – DOES A BLIND DOSIS FITS ALL?
by: Nuno Henriques Coelho, et al.
Published: (2019-05-01) -
The endothelium is the main target of coronavirus infection
by: M.V. Bondar, et al.
Published: (2022-04-01) -
The Changing Landscape of Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation: Use of the Direct Thrombin Inhibitors
by: Cindy Neunert, et al.
Published: (2022-07-01)